However, fewer companies have worked on vaccines and drugs for the MERS virus, according to Reuters. Small biotech companies such as Greffex,
The UC Berkeley team realized that the only way to clarify such vague classifications was to sequence the genomes of these organisms,
Colleagues at the Department of energy Joint Genome Institute shotgun-sequenced the DNA of all the microbes in the filtered sample,
a technique known as metagenomic analysis. Banfield team then assembled the millions of DNA pieces into eight complete bacterial genomes from four new and one previously studied phyla,
and draft genomes most of them more than 90 percent complete for 789 other bacteria. They are lumping the 35-plus phyla into a cluster they call the andidate phyla radiationbecause of their similarities to one another
and Microbial Biology at UC Berkeley. o one had been able to put all the pieces together before.
and small genomes, may be the reason they can be grown in lab culture: they are stripped-down life forms with the barebones requirement of genes,
The new discovery allowed the team not only to define about a third of all bacterial phyla but, thanks to the nearly complete genomes
the multi-protein machines that translate genetic instructions into proteins. he unusual ribosomes, the small genomes between 600 and 1,
There is a lot of biology that we haven been able to understand from our current methods, Brown said.
most after award-winning microbiologists but one Berkelbacteria after UC Berkeley. The work is supported by the Department of energy.
This discovery gives a new understanding to genetic diseases that are caused by mutations in these proteins.
a professor in Salk Molecular and Cell biology Laboratory and senior author of the new paper. hope people start to accept
Hetzer suspects that other nucleoporins also have roles in gene expression control, but cautions that the roles could be very differentach nucleoporin,
Mutations in many nucleoporin genes has been linked to human diseases and developmental disorders, including some forms of leukemia and inherited heart problems.
researchers have assumed the mutations led to disease by altering the transport of proteins in and out of a cell nucleus. ow,
and developmental disorders might actually be caused by the ability of these genes to regulate gene expression programs.
biocompatible materials, said co-senior author Zhen Gu, Ph d.,a professor in the Joint UNC/NC State department of Biomedical engineering.
"said first author Alphonsus Ng who recently graduated with a Phd from the U of T Institute of Biomaterials and Biomedical engineering (IBBME) and Donnelly Centre,
the implications for human biology are indirect at best. owever, mouse brains have long been accepted as excellent basic research models for the human brain,
Earlier this month, MIT spinout Microchips Biotech partnered with a pharmaceutical giant to commercialize its wirelessly controlled, implantable,
Invented by Microchips Biotech cofounders Michael Cima, the David H. Koch Professor of Engineering, and Robert Langer, the David H. Koch Institute Professor, the microchips consist of hundreds of pinhead-sized reservoirs,
and osteoporosis. Now Microchips Biotech will begin co-developing microchips with Teva Pharmaceutical, the world largest producer of generic drugs,
Apart from providing convenience, Microchips Biotech said these microchips could also improve medication-prescription adherence a surprisingly costly issue in the United states. A 2012 report published in the Annals of Internal medicine estimated that Americans who don stick to prescriptions rack up $100 billion
Microchips Biotech will continue work on its flagship product, a birth-control microchip, backed by the Bill and Melinda Gates Foundation,
Cima, who now serves on the Microchips Biotech board of directors with Langer, sees this hormone-releasing microchip as one of the first implantable rtificial organsbecause it acts as a gland. lot of the therapies are trying to chemically trick the endocrine systems Cima said. e are doing that with this artificial organ we created.
For years, the technology underwent rigorous research and development at Microchips Biotech. But in 2011, Langer and Cima,
MEMS innovations Microchips Biotech made several innovations in the microelectromechanical systems (MEMS) manufacturing process to ensure the microchips could be commercialized.
To do so, Microchips Biotech modified a cold-welding ongue and grooveprocess. This meant depositing a soft,
and target research on"hotspots"most likely to be important for biological function. Known as SAPH-ire (Structural Analysis of PTM Hotspots), the tool could accelerate the search for potential new drug targets on protein structures,
"SAPH-ire predicts positions on proteins that are likely to be important for biological function based on how many times those parts of the proteins have been found in a chemically-modified state
"explained Matthew Torres, an assistant professor in the School of Biology at the Georgia Institute of technology.""SAPH-ire is a tool for discovery,
"The tool and its proof-of-concept testing were reported June 12 in the journal Molecular and Cellular Proteomics.
Through modern mass spectrometry proteomics techniques, scientists have identified more than 300,000 post-translational modifications (PTMS) in different families of proteins across numerous species. These PTMS come in many forms, resulting
which we can understand what they do, from a classical biochemical approach. You have so much information that you don't know where to begin."
"Each PTM hotspot can then be ranked in order of highest to lowest potential for having significant biological function."
and they expect to see their program become part of informatics systems used to analyze large volumes of proteomics data emerging from labs around the world."
"Connecting SAPH-ire to other programs that convert mass spec data into actual PTM data could provide immediate biological relevance and prioritization for biochemists and others.
#New Single-use Harvesting Technology for High Cell Density Cultures Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has introduced Sartoclear Dynamics,
Sartorius Stedim Biotech has developed now this robust technology for biotech applications. Specially designed for cgmp processing
Nowadays, 2, 000 L is a standard size for single-use bioreactors, but a centrifuge is required still for removing cells from such volumes.
which is attractive for newcomers from emerging biotech markets. The ready-to-use clarification system enables harvesting of high cell density cultures up to 2, 000 liters 0
. E. P. Taylor Professor of Pain Studies at Mcgill University and Director of the Alan Edwards Centre for Research on Pain. he realization that the biological basis for pain between men and women
. assistant professor in the Department of Ophthalmology and a researcher in UNC Gene therapy Center and Carolina Institute for Developmental Disabilities, developed the experimental treatment in studies conducted at UNC.
This trial is the first in history to deliver gene therapy through the spinal fluid to test the potential to achieve broad treatment of the spinal cord and brain (central nervous system or CNS.
and wee already seeing clear application of this approach to treat other diseases studied in my lab. ray serves as an associate investigator on the trial as does R. Jude Samulski, Ph d.,director of the UNC Gene therapy Center."
"This specific study represents a culmination of years of basic research from the UNC Gene therapy Center
if we could'help save her child',to last week gene therapy administration; a remarkable and humbling journey that I privileged to be a part of."
"This first intrathecal (into the spinal fluid) delivery of a viral gene therapy vector in a human patient is a fundamental step towards developing a causal treatment for giant axonal neuropathy (GAN), a devastating progressive neurogenetic
#Microarray for Research into Haematological and Solid Cancers Oxford Gene Technology (OGT) released a new microarray designed to improve the accuracy and efficiency of cancer research.
because theye so hard to study, said Tony Hunter, American Cancer Society Professor, holder of the Dulbecco Chair in the Salk Molecular and Cell biology Laboratory and senior author of the new paper.
Nanotechnology, Biology and Medicine, was led by Jeffrey Zink and Fuyu Tamanoi, both members of the California Nanosystems Institute and Jonsson Comprehensive Cancer Center at UCLA,
who also is a professor of microbiology, immunology and molecular genetics and a director of the signal transduction and therapeutics program at the Jonsson Cancer Center. his demonstrates the effectiveness of our treatment
and encourages us to explore further what is happening to the tumor. In previous studies
sirna has been shown to effectively shut down gene expression in tumor cells grown in the laboratory. But the technique had not been effective in living organisms
who also is distinguished a UCLA professor of chemistry and biochemistry and a pioneer in the design and synthesis of multifunctional mesoporous silica nanoparticles u
Anstie told Bioscience Technology. ather than sniffing out a variety of smells as a dog would,
Anstie told Bioscience Technology, ther conditions, although they have a clear molecular signature in the breath may be masked by the general complexity involved in getting a good repeatable sample.
such strains are only found at low levels within the human gut, according to Timothy Lu, an associate professor of biological engineering and of electrical engineering and computer science,
a professor of biological engineering at MIT. e wanted to work with strains like B. thetaiotaomicron that are present in many people in abundant levels,
The team developed a series of genetic parts that can be used to precisely program gene expression within the bacteria. sing these parts
we could engineer bacteria to detect multiple biomarkers, and only trigger a response when they are all present.
Tom Ellis, group leader of the Centre for Synthetic biology at Imperial College London, who was involved not in the research,
said the paper takes many of the best tools that have been developed for synthetic biology applications with E coli
or biosensors, in bacteria that are placed then in the gut, this paper stands out from the crowd by first engineering a member of the Bacteroides genus,
was carried out in collaboration with the School of Biochemistry at the University of Bristol, the Wound Biology Group at the Cardiff Institute of Tissue Engineering and Repair,
In experiments published in the journal Nature Communications, the researchers used biochemical and biophysical cues to prompt stem cells to differentiate
said Kevin Healy, a UC Berkeley professor of bioengineering, who is co-senior author of the study with Dr. Bruce Conklin,
a senior investigator at the Gladstone Institute of Cardiovascular disease and a professor of medical genetics and cellular and molecular pharmacology at UC San francisco. his technology could help us quickly screen for drugs likely to generate cardiac birth defects,
which are critical to the development of heart tissue. his spatial differentiation happens in biology naturally,
a UC Berkeley postdoctoral researcher in bioengineering. he confined geometric pattern provided biochemical and biophysical cues that directed cardiac differentiation and the formation of a beating microchamber.
said Warren Ruder, an assistant professor of biological systems engineering in both the College of Agriculture and Life sciences and the College of Engineering."
For future experiments, Ruder is building real-world robots that will have the ability to read bacterial gene expression levels in E coli using miniature fluorescent microscopes.
understanding the biochemical sensing between organisms could have far reaching implications in ecology, biology, and robotics.
engineered gene circuits in E coli, microfluid bioreactors, and robot movement. The bacteria in the mathematical experiment exhibited their genetic circuitry by either turning green or red, according to
Ruder conducted his research in collaboration with biomedical engineering doctoral student Keith Heyde, of Wilton, Connecticut, who studies phyto-engineering for biofuel synthesis. e hope to help democratize the field of synthetic biology for students and researchers all over the world with this model,
said Ruder. n the future, rudimentary robots and E coli that are used already commonly separately in classrooms could be linked with this model to teach students from elementary school through the Ph d.-level about bacterial relationships with other organisms. ource:
a clinical stage biopharmaceutical company which owns the core T-cell receptor technology and funded the study.
According to Adaptimmune, the trial is published the first study of lentiviral vector mediated TCR gene expression in humans.
professor in Microbiology-Immunology and Medicine-Infectious disease. hese findings lay the foundation for future studies to further understand the mechanisms for how the escape to the bloodstream occurs.
professor of stem cell biology in the School of medicine led the research project, iscovery of a Novel Polymer for Human Pluripotent Stem Cell Expansion and Multilineage Differentiation. he possibilities for regenerative medicine are still being reached in the form of clinical trials,
said Stephen Beverley, Ph d.,senior author of one of the studies and the Marvin A. Brennecke Professor and head of the Department of Molecular Microbiology at Washington University School of medicine in St louis. n the future,
scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
and inexpensively edit genetic information in virtually any organism. T cells, which circulate in the blood, are an obvious candidate for medical applications of the technology,
But in practice, editing T cell genomes with CRISPR/Cas9 has proved surprisingly difficult, said Alexander Marson, Ph d.,a UCSF Sandler Fellow,
said that the research is a significant step forward in bringing the power of CRISPR/Cas9 editing to human biology
and allows new genetic sequences to be inserted, has generally been introduced into cells using viruses or circular bits of DNA called plasmids.
(or nock in specific new sequences to correct mutations in T cells. As will be reported online in Proceedings of the National Academy of Sciences during the week of July 27
so there increasing clinical infrastructure that we could potentially piggyback on as we work out more details of genome editing,
associate professor and senior Cancer Research UK Fellow at the division of biomedical cell biology at Warwick Medical school.
s a cell biologist you dream of finding a new structure in cells but it so unlikely.
when they divide each new cell has a complete genome. Mitotic spindles are made of microtubules
A cell needs to share chromosomes accurately when it divides otherwise the two new cells can end up with the wrong number of chromosomes.
This is called aneuploidy and this has been linked to a range of tumours in different body organs.
The mitotic spindle is responsible for sharing the chromosomes and the researchers at the University believe that the mesh is needed to give structural support.
and cells had trouble sharing chromosomes during division. Dr Emma Smith, senior science communications officer at Cancer Research UK, said:
roblems in cell division are common in cancer cells frequently end up with the wrong number of chromosomes.
This early research provides the first glimpse of a structure that helps share out a cell chromosomes correctly
Warwick Medical school division of biomedical cell biology carries out fundamental molecular and cellular research into biomedical problems.
Without a molecular understanding of the underlying cell biology, intelligent directed therapeutic intervention is impossible. The division research focuses on fundamental cell biology processes such as cell division and intracellular communication.
Hey, check out all the research scientist jobs. Post your resume today s
#Could Dissolvable Microneedles Replace Injected Vaccines? Osaka University Study Eric is terrified. He stands outside the clinic and takes a few deep breaths before walking slowly through the automatic doors.
according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch the only vaccination system of its kind could make vaccination easier, safer and less painful.
one of the authors of the study and Professor of Biotechnology and Therapeutics at the Graduate school of Pharmaceutical Sciences at Osaka University. ecause the new patch is so easy to use,
suggests research published today in the journal Nature Genetics. The ytospongesits within a pill which,
and the genetic mutations involved could help doctors catch the disease earlier, offering better treatment options for the patient.
However, researchers from the University of Cambridge have shown that variations in mutations across the oesophagus mean that standard biopsies may miss cells with important mutations.
A sample was more likely to pick up key mutations if taken using the Cytosponge, developed by Professor Rebecca Fitzgerald at the Medical Research Council Cancer Unit at the University of Cambridge. he trouble with Barrett oesophagus is that it looks bland
explains Professor Fitzgerald. e created a map of mutations in a patient with the condition
Some might carry an important mutation, but many will not. If youe taking a biopsy, this relies on your hitting the right spot.
Professor Fitzgerald and colleagues carried out whole genome sequencing to analyse paired Barrett oesophagus and oesophageal cancer samples taken at one point in time from 23 patients,
The researchers found patterns of mutations in the genome where one etterof DNA might change to another,
Even in areas of Barrett oesophagus without cancer, the researchers found a large number of mutations in their tissue on average 12,000 per person (compared to an average of 18,000 mutations within the cancer.
Many of these are likely to have been ystanders genetic mutations that occurred along the way but that were implicated not actually in cancer.
where a patient would go from having lots of individual mutations, but no cancer, to a situation where large pieces of genetic information were being transferred not just between genes but between chromosomes.
Co-author Dr Caryn Ross-Innes adds: e know very little about how you go from pre-cancer to cancer
Barrett oesophagus and the cancer share many mutations, but we are now a step closer to understanding
which are the important mutations that tip the condition over into a potentially deadly form of cancer.
along with Dino Di Carlo, professor of bioengineering, and Omai Garner, associate director of clinical microbiology for the UCLA Health System.
UCLA undergraduate Brandon Berg was the study first author, and two other undergraduates also contributed to the research. t is quite important to have these kinds of mobile devices,
and Bioengineering. his mobile platform can be used for point-of-care testing, screening populations for particular diseases,
This mobile platform was compared with the standard FDA-approved well-plate readers in a UCLA clinical microbiology laboratory.
The UCLA team included researchers from electrical engineering, physics and astronomy, bioengineering, pathology and laboratory medicine,
and Michael Lewinski, an adjunct faculty in UCLA bioengineering department. This research was supported by the National Science Foundation and the Howard hughes medical institute h
the research team included Professor Vladimir Tsukruk from the Georgia Tech School of Materials science and engineering and Rajesh Naik, Biotechnology Lead and Tech Advisor of the Nanostructured and Biological Materials Branch
and by Georgia Tech Renewable Bioproducts Institute Fellowship. The content is solely the responsibility of the authors
says Jeffrey Karp, a bioengineer at Brigham and Women Hospital in Boston, Massachusetts. ne of the greatest implications of the work is to track thousands of cells simultaneously with a single technique,
The engineered ribosome may enable the production of new drugs and next-generation biomaterials and lead to a better understanding of how ribosomes function.
The artificial ribosome, called Ribo-T, was created in the laboratories of Alexander Mankin, director of the UIC College of Pharmacy's Center for Biomolecular Sciences
and Northwestern's Michael Jewett, assistant professor of chemical and biological engineering. The human-made ribosome may be able to be manipulated in the laboratory to do things natural ribosomes cannot do.
or producing designer therapeutics--and perhaps one day even non-biological polymers. No one has developed ever something of this nature."
"Our new protein-making factory holds promise to expand the genetic code in a unique and transformative way, providing exciting opportunities for synthetic biology and biomolecular engineering,
Professor Elizabeth Hartland, head of the department of Microbiology and Immunology at the University of Melbourne added that the international collaboration has brought together the immunological expertise in Melbourne
as a result of collaboration between Kobe-based medical device manufacturer My Tech researchers from Showa University uses a biochip,
'published this month in Biomaterials. The authors further explained that the new delivery mechanism uses a dissolvable material,
Even better news is that the transgenic cats have passed successfully both traits (glowing and resistance) along to their offspring.
#State Deficits to Shrink & Taxes Drop-Good News for Biotech Forecasters at the National Conference of State Legislatures2011 Legislative Summit expect a dramatic reduction of state deficits in the coming years,
Unfortunately these corporate tax cuts do not provide much-needed capital to small biotech companies because their lack of profits makes tax benefits unredeemable.
Most emerging biotech companies with promising scientific innovation are small, research-intensive and not yet profitable because they do not have approved an FDA product on the market.
Biotech start-ups generally struggle to raise capital to finance their research, and BIO advocates two important policies that enable them to continue critical R&d of advancements and breakthroughs.
The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.
a rare hereditary disease in which a mutation of the MEN1 gene on chromosome 11 makes patients susceptible to developing both benign
Animal studies previously linked this gene mutation with breast cancer; and the researchers further conducted an analysis of the utchmen1 Study Groupdatabase.
Right now there are 400 patients in The netherlands with this mutation. Breast cancer is a leading killer for women.
#Biodiesel production from Sugarcane A multi-institutional team led by plant biology professor Stephen P. Long from the University of Illinois reports that it can increase sugarcane's geographic range boost its photosynthetic rate by 30 percent
Using genetic engineering the researchers increased photosynthetic efficiency in sugarcane and sorghum by 30 percent Long said.
Long is an affiliate of the Institute for Genomic Biology at the University of Illinois s
#Uniting To Accelerate Pediatric Medicine Drug companies inherently absorb significant risk when developing compounds and biologics for clinical use.
I have noticed a promising trend the rise of open source drug R&d consortia that include large biotech
and biotech companies to develop better treatments most recently with Shire around rare diseases. These alliances leverage Boston Children research expertise and companiesdevelopment and commercialization capabilities.
generating creative initiatives from universities, tech transfer organizations, government and biotechs. BIO-X is an open innovation vehicle run by Uppsala BIO.
and small biotechs, offering to support their ideas through to proof of principle. or the proposals selected,
#Biotechnology Helps Meet Consumer Demand for Earth-Friendly Products Industrial biotechnology has its roots in cleaning up environmental hazards.
Today, biotechnology enables manufacturers to make sustainable products with renewable material, instead of oil, and to use less energy in the manufacturing process A recent Roundtable discussion hosted by the Industrial biotechnology Journal
and printed in its April edition features academic experts and executives from industrial biotechnology and consumer product companies discussing demand for sustainable products.
Visit Journal publisher Maryann Liebert at Booth 3617 in the BIO Exhibition. Consumers are looking for products that are safer,
Vice president of Global Sales and Applications for Dupont Industrial Biosciences. bout 80 percent of U s. consumers say they will buy green products
The $3. 5 trillion global chemicals market represents a significant opportunity for growth of industrial biotechnology that ultimately provides consumers a choice of safer, cleaner products f
#Wall street journal Highlights Promising Gene therapy Advances Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American Society of Hematology.
have been able to forgo transfusions for at least five months following a gene therapy treatment from bluebird.
Advances such as this show the promise of biotechnology to transform lives and enable patients who had relied previously on frequent,
and women at biotechnology companies across the world are working hard to advance every day. Read the full Wall street journal article here r
Industrial biotechnology continues to enable solutions to energy challenges and building a biobased economy is key to reducing dependence on foreign oil enhancing our nation economic and energy security.
Last week, the U s. Navy signed an agreement with biotech company Biodico to collaborate on developing advanced biofuels and bioenergy refineries throughout the globe for the U s. military.
The biopharmaceutical industry is an important contributor to U s. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion
As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors in the U s. It is becoming clear,
however, that the U s. can no longer take its leadership in biopharmaceuticals or other knowledge-based industries for granted.
many of which are targeted to the biopharmaceutical industry and related sectors. Despite the short-term costs associated with these investments,
As a result, more and more, the U s. is competing globally to maintain its leadership position in biopharmaceuticals.
For purposes of this study, entitled The Biopharmaceutical Research and development Enterprise: Growth Platform for Economies Around the World, Battelle examined policies
and programs being implemented to promote the bioscience sector in 18 countries and the European union (E u.).These countries were selected because of their interest in growing an innovation economy.
In addition, countries selected include a mix of developed countries with an existing biopharmaceutical presence (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, Sweden, the United kingdom UK,
and the E u. as a whole) and emerging countries that are targeting the biopharmaceutical sector (Brazil, Chile, China, Russia, Saudi arabia, Singapore, South africa, and South korea).
and capital, all of the countries examined are focusing on strategic components to grow their biopharmaceutical economy.
and programs to increase the economic footprint of the biopharmaceutical and related sectors in their own countries.
America innovative biopharmaceutical companies face increasing challenges, ranging from the cost and increased complexity of bringing new medicines to patients, the prospect of attracting
Just as other countries have drawn lessons from the growth of the U s. biopharmaceutical sector so too can the U s. learn from other countries that are strategically
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011